StreetInsider.com News Articles

MediciNova reaches 200-patient enrollment in NIH-funded ALS study

Wed, 15 Jul 2026 08:03:53 -0400

MediciNova, Inc. (NASDAQ: MNOV) announced that the SEANOBI-ALS expanded access study evaluating MN-166 (ibudilast) in patients with amyotrophic lateral sclerosis has reached its target enrollment of 200 patients.

The study, funded by the National Institute of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health under the ACT for ALS program, is designed to provide MN-166 to ALS patients who are not eligible to participate in ongoing randomized clinical trials. Final patient follow-ups are projected to conclude in early 2027, after which a data analysis phase will begin to support scientific presentations and peer-reviewed publications led by an academic

MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients

Wed, 15 Jul 2026 08:00:00 -0400

LA JOLLA, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the target enrollment of 200 patients has been achieved in the SEANOBI-ALS study (Scalable Expanded Access with Analysis of Neurofilament and Other Biomarkers in ALS ; NCT 06743776) evaluating MN‑166 (ibudilast) in patients with amyotrophic lateral sclerosis (ALS).

The Expanded Access Program SEANOBI study is funded by National Institute of Neurological Disorders and Stroke (NINDS) National Institutes of

MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients

Wed, 15 Jul 2026 08:00:00 -0400

The Expanded Access Program SEANOBI study is funded by National Institute of Neurological Disorders and Stroke (NINDS) National Institutes of

MediciNova completes last patient visit in NAFLD Phase 2 trial

Tue, 30 Jun 2026 08:01:28 -0400

MediciNova, Inc. (NASDAQ: MNOV) announced the completion of the last patient last visit in its Phase 2 clinical trial evaluating MN-001 (tipelukast) for hypertriglyceridemia and nonalcoholic fatty liver disease associated with type 2 diabetes mellitus, according to a shareholder letter from CEO Yuichi Iwaki.

The trial, designated MN-001-NATG-202, is a multicenter, randomized, double-blind, placebo-controlled study. Top-line data are expected in the third quarter of 2026.

On its other lead compound, MN-166 (ibudilast), the company said 100 patients have been enrolled across 12 activated U.S. sites in the SEANOBI expanded-access program evaluating ibudilast in amyotrophic lateral sclerosis patients, representing half of the planned

MediciNova CEO Provides Shareholder Update

Tue, 30 Jun 2026 08:00:00 -0400

LA JOLLA, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today provides shareholders a corporate update in the following Letter to Stockholders from CEO Yuichi Iwaki, M.D., Ph.D.

Dear Fellow Shareholders,

MediciNova continues to make significant progress across its key programs, most recently anchored by the completion of the last patient last visit in our Phase 2 clinical trial of MN-001-NATG-202 evaluating MN-001 (tipelukast) for the treatment of hypertriglyceridemia and

MediciNova CEO Provides Shareholder Update

Tue, 30 Jun 2026 08:00:00 -0400

Dear Fellow Shareholders,

Form 4 MEDICINOVA INC For: Jun 23 Filed by: Nagao Hideki

Thu, 25 Jun 2026 16:38:00 -0400

si-local-file:///var/storage/secattach/20260625/26692944.html

Form 4 MEDICINOVA INC For: Jun 23 Filed by: Nagao Hideki

Thu, 25 Jun 2026 16:38:00 -0400

si-local-file:///var/storage/secattach/20260625/26692944.html

Form 4 MEDICINOVA INC For: Jun 23 Filed by: BEAVER CAROLYN

Thu, 25 Jun 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260625/26692889.html

Form 4 MEDICINOVA INC For: Jun 23 Filed by: BEAVER CAROLYN

Thu, 25 Jun 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260625/26692889.html

Form 4 MEDICINOVA INC For: Jun 23 Filed by: Lemerond Nicole

Thu, 25 Jun 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260625/26692891.html

Form 4 MEDICINOVA INC For: Jun 23 Filed by: Lemerond Nicole

Thu, 25 Jun 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260625/26692891.html

Form 8-K MEDICINOVA INC For: Jun 23

Wed, 24 Jun 2026 16:39:00 -0400

si-local-file:///var/storage/secattach/20260624/26686111.html

Form 8-K MEDICINOVA INC For: Jun 23

Wed, 24 Jun 2026 16:39:00 -0400

si-local-file:///var/storage/secattach/20260624/26686111.html

MediciNova receives patent allowance for glioblastoma combination therapy

Mon, 08 Jun 2026 08:00:09 -0400

MediciNova Inc. (NASDAQ: MNOV) received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application covering the use of ibudilast (MN-166) in combination with anti-PD-1 antibodies for treating glioblastoma, the company announced.

The patent, expected to expire no earlier than September 2042, covers multiple treatment parameters including dosing regimen, route of administration, and duration of therapy. The allowed claims encompass combinations with multiple anti-PD-1 antibodies across various treatment conditions.

"This Notice of Allowance further strengthens our intellectual property estate for MN-166 in glioblastoma and supports continued evaluation of ibudilast-based combination strategies in this aggressive malignancy," said Dr.

MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment

Mon, 08 Jun 2026 08:00:00 -0400

LA JOLLA, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application that covers the use of ibudilast (MN-166) in combination with an immune checkpoint inhibitor, specifically an anti-PD-1 antibody, for the treatment of glioblastoma. This patent allowance is expected to further strengthen the intellectual property position supporting the Company’s combination therapy development strategy.

MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment

Mon, 08 Jun 2026 08:00:00 -0400

MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

Tue, 26 May 2026 19:00:00 -0400

LA JOLLA, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the completion of last patient last visit (LPLV) in its Phase 2 clinical trial, MN-001-NATG-202, evaluating MN-001 (tipelukast) for the treatment of hypertriglyceridemia and nonalcoholic fatty liver disease (NAFLD) associated with type 2 diabetes mellitus (T2DM).

The MN-001-NATG-202 study is a multicenter, randomized, double-blind, placebo-controlled trial evaluating MN-001 (tipelukast). Patients were randomized 1:1 to receive either 500 mg/day of MN-001

MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

Tue, 26 May 2026 19:00:00 -0400

The MN-001-NATG-202 study is a multicenter, randomized, double-blind, placebo-controlled trial evaluating MN-001 (tipelukast). Patients were randomized 1:1 to receive either 500 mg/day of MN-001

Form 10-Q MEDICINOVA INC For: Mar 31

Thu, 14 May 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260514/26495212.html

Form 10-Q MEDICINOVA INC For: Mar 31

Thu, 14 May 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260514/26495212.html

Form ARS MEDICINOVA INC For: Dec 31

Wed, 29 Apr 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260429/26395794.html

Form ARS MEDICINOVA INC For: Dec 31

Wed, 29 Apr 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260429/26395794.html

Form DEFA14A MEDICINOVA INC

Wed, 29 Apr 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260429/26395711.html

Form DEFA14A MEDICINOVA INC

Wed, 29 Apr 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260429/26395711.html